GlaxoSmithKline plc (the 'Company')
Transaction notification
The following amendments have been made to the 'Director/PDMR Shareholding' announcement released on 26 April 2018 at 15:30 under RNS No 2887M.
Dr Jesse Goodman acquired 411.275 notional American Depositary Shares ('ADSs') and not 623.699 notional ADSs as originally announced. Ms Judy Lewent acquired 458.278 notional ADSs and not 694.979 notional ADSs as originally announced.
A small number of non-material typographical changes have also been made to the announcement. The changes are identified by an asterisk (*).
All other details remain unchanged. The full amended text is shown below.
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Sir Philip Hampton |
||||
b) |
Position/status |
Non-Executive Chairman |
||||
c) |
Initial notification/ amendment |
Amendment |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2018 to 31 March 2018.
|
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
n/a (single transaction) |
||||
e) |
Date of the transaction |
2018-04-25 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Professor Sir Roy Anderson |
||||
b) |
Position/status |
Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Amendment |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2018 to 31 March 2018.
|
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
n/a (single transaction) |
||||
e) |
Date of the transaction |
2018-04-25 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr Vindi Banga |
||||
b) |
Position/status |
Senior Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Amendment |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2018 to 31 March 2018.
|
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
n/a (single transaction) |
||||
e) |
Date of the transaction |
2018-04-25 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Dr Vivienne Cox |
||||
b) |
Position/status |
Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Amendment |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2018 to 31 March 2018.
|
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
n/a (single transaction) |
||||
e) |
Date of the transaction |
2018-04-25 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Ms Lynn Elsenhans |
||||
b) |
Position/status |
Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Amendment |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
||||
b) |
Nature of the transaction |
Acquisition of notional ADSs* under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2018 to 31 March 2018.
|
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
n/a (single transaction) |
||||
e) |
Date of the transaction |
2018-04-25 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Dr Laurie Glimcher |
||||
b) |
Position/status |
Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Amendment |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
||||
b) |
Nature of the transaction |
Acquisition of notional ADSs* under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2018 to 31 March 2018.
|
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
n/a (single transaction) |
||||
e) |
Date of the transaction |
2018-04-25 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Dr Jesse Goodman |
||||
b) |
Position/status |
Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Amendment |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
||||
b) |
Nature of the transaction |
Acquisition of notional ADSs* under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2018 to 31 March 2018.
|
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
n/a (single transaction) |
||||
e) |
Date of the transaction |
2018-04-25 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Ms Judy Lewent |
||||
b) |
Position/status |
Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Amendment |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs') ISIN: US37733W1053
|
||||
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2018 to 31 March 2018*. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
n/a (single transaction) |
||||
e) |
Date of the transaction |
2018-04-25 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr Urs Rohner |
||||
b) |
Position/status |
Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Amendment |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2018 to 31 March 2018.
|
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
n/a (single transaction) |
||||
e) |
Date of the transaction |
2018-04-25 |
||||
f) |
Place of the transaction
|
n/a |